Heart Monitor Trial Tests New Approach to Unexplained Fainting

The New England Journal of Medicine has shared findings from the ASPIRED trial, which looked at a specific clinical question: does initiating cardiac monitoring straight after emergency evaluation improve outcomes for patients who faint without any clear explanation? The trial’s results have been summarised in a short video published by the journal.

Unexplained fainting — known medically as syncope — can have a range of causes, from relatively minor to potentially serious heart rhythm problems. Working out the cause quickly matters, because some underlying conditions carry a risk of further episodes or more serious events. The timing of monitoring is one of the key variables doctors can control in that diagnostic process.

However, it is important to note that the trial did not meet its primary endpoint: the number of self-reported fainting episodes after one year was not significantly reduced by early monitoring compared with standard care (1.37 vs 1.58 episodes; p=0.43). The trial did, according to its findings, demonstrate improvements in secondary outcomes, including improved arrhythmia detection, faster diagnosis, and increased treatment rates — though these should be considered in the context of the primary endpoint not being met.

The research was presented at ESC Congress, the annual meeting of the European Society of Cardiology, one of the largest gatherings of heart specialists in the world.

The NEJM’s Quick Take format condenses trial findings into a brief video summary — useful for clinicians and patients who want the headline results without reading a full research paper.

Anyone who has experienced an unexplained fainting episode should speak to their GP in the first instance. If someone faints and does not regain consciousness quickly, call 999. For non-emergency health concerns, NHS 111 is available by phone or online at any time.